...MAO-A in patients with prostate cancer. Krenitsky Pharmaceuticals Inc. has the reversible MAO-A inhibitor TriRima (KP157...

...trial to evaluate 125 mg TriRima twice daily in 360 patients. CeNeRx has rights to TriRima...
...N.C. Krenitsky Pharmaceuticals Inc. , Durham, N.C. Product: TriRima ( KP157 ) (formerly CX157 , Tyrima...

...start a Phase II trial for TriRima as monotherapy for treatment-resistant depression by year end. TriRima...
...A (MAO-A) that elevates the levels of serotonin, norepinephrine and dopamine. CeNeRx has rights to TriRima...

...chemotherapy-induced peripheral neuropathy this year. Financial terms were not disclosed. CeNeRx's lead is TriRima (formerly Tyrima...
...norepinephrine and dopamine is in Phase II testing to treat depression. CeNeRx has rights to TriRima...

...CeNeRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 60 mg of oral Tyrima...
...6 weeks in about 272 patients. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...

...by existing investor Aisling. L Capital Partners and Pappas Ventures, also existing investors, participated. CeNeRx's Tyrima...

...oral Tyrima in over 270 patients. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...

...company’s Phase I program, which included acute dosing, repeat dosing and fed-fasted studies, showed that Tyrima...
...allow for once- or twice-daily dosing. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...

...In a single-dose, dose-escalation, placebo-controlled, U.S. Phase I trial in 41 healthy volunteers, Tyrima was well...
...is slated to being next quarter. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...

...are used sparingly because of potentially lethal dietary and drug interactions. CeNeRx BioPharma Inc. believes Tyrima...
...aged meats and cheeses. Elevated tyramine can result in hypertensive crisis. CEO Barry Brand said Tyrima...
...Phase I testing of Tyrima in 1H07. Brand said the company also will administer both Tyrima...